Industry Explorers Blaze On
-
Insurance Strategies For Sustainable Growth And Risk Management
10/2/2023
Now is the time for company leaders at all stages to evaluate insurance costs, which can be among the top five most significant budget line items.
-
Unlocking The Power Of Empathy In Employee And Customer Experiences
10/2/2023
By fostering empathy within the workplace, organizations can create a remarkable employee experience that drives employee engagement, customer satisfaction, and, ultimately, business success.
-
From Robotics To AI … Yesterday’s Unknown Is Tomorrow’s Promise
10/2/2023
As part of my professional consulting and patient advocacy work in healthcare, I have learned about AI and seen first-hand the difference it is already making for countless patients and physicians around the world.
-
Sterile Injectable Life Cycle Management
10/2/2023
In a recent study on the market outlook for sterile injectable drug product manufacturing, ISR asked respondents whether their company is investigating improving or extending the life cycle of sterile injectable drug products in their portfolio.
-
Safeguarding Biopharmas From Product Shortages
10/2/2023
The COVID-19 pandemic is just one example of the types of supply chain disruptions that life sciences companies faced. It is important to understand there are key considerations that can help life sciences businesses prepare for and respond to product shortages.
-
Leading A Successful Back Office Transformation
10/2/2023
This article will lay out the types of events that should trigger additional investment in back office systems along with key decisions to help ensure a successful project.
-
Key Takeaways From The FDA Guidance On DCTs
10/2/2023
The FDA brought out “The Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency” in a bid to continue clinical trials during the COVID-19 pandemic. There were several measures that were included like the use of EHRs and the use of digital health devices. In May, this year, they provided guidelines for conducting DCTs. In this article we will explore some of the highlights of the FDA guidance for DCTs.
-
How Can Leaders Balance Requests Of Employees To Continue Remote Working With The Need For Increased Business Efficiency And Achieving Strong Dynamics Among A Management Team?
10/2/2023
See the answer from David Pyott, chairman at London Business School, a board member at Alnylam Therapeutics, and the former chairman and CEO of Allergan.
-
Given Drug Development Time Horizons, How Does A Company Best Navigate The Inevitable Vagaries Of Investor Therapeutic/Modality Sentiment And Its Collateral Consequences On Funding?
10/2/2023
See the answer from Allan Shaw, an independent consultant and chief financial officer at Portage Biotech.
-
How Do Outsourcers Feel About The CDMO Industry?
10/2/2023
Now is the time for company leaders at all stages to evaluate insurance costs, which can be among the top five most significant budget line items.